Skip to content

SGM-LARRC: Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for locally advanced or recurrent rectal cancerpatients undergoing curative surgery.

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-510768-21-00
Acronym
NL69838.056.19
Enrollment
203
Registered
2024-10-01
Start date
2019-10-16
Completion date
Unknown
Last updated
2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Brief summary

The primary endpoint is the rate of patients with R0 resections. This endpoint is based on the primary objective of clinical benefit of FGOS combined with SGM-101 as the intraoperative imaging agent.

Detailed description

Concordance between intraoperative fluorescence assessment of resected lesions and their histopathology., For every removed specimen: rate of false negatives, false positives, true negatives and true positives concerning fluorescence, with histopathology as the gold standard., Tumor to background ratio (TBR) for fluorescence in malignant and benign tissue., Modification of operative plan due to imaging (e.g. more/less extensive resection or adjustment of IORT) and change in postoperative treatment will be recorded., 30-day mortality and 30-day complication rates., 2-year overall survival, 2-year disease free survival and 2-year local recurrence free survival.

Interventions

Sponsors

Academisch Ziekenhuis Leiden
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the rate of patients with R0 resections. This endpoint is based on the primary objective of clinical benefit of FGOS combined with SGM-101 as the intraoperative imaging agent.

Secondary

MeasureTime frame
Concordance between intraoperative fluorescence assessment of resected lesions and their histopathology., For every removed specimen: rate of false negatives, false positives, true negatives and true positives concerning fluorescence, with histopathology as the gold standard., Tumor to background ratio (TBR) for fluorescence in malignant and benign tissue., Modification of operative plan due to imaging (e.g. more/less extensive resection or adjustment of IORT) and change in postoperative treatment will be recorded., 30-day mortality and 30-day complication rates., 2-year overall survival, 2-year disease free survival and 2-year local recurrence free survival.

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026